The Federal Circuit has lifted an injunction that previously restricted Avadel CNS Pharmaceuticals from conducting clinical trials for its sleep disorder treatments. Although the initial injunction has been lifted, the infringement case has been remanded to Delaware to assess if a future injunction should be dictated by the Hatch-Waxman Act. The Federal Circuit’s decision presents an important question for pharmaceutical law, which could have significant implications for the governance of such cases in the future.
Details on the proceedings can be explored further through this report.